CF
TRDA icon

Cantor Fitzgerald’s Entrada Therapeutics TRDA Stock Holding History

Cantor Fitzgerald’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$593K Sell
47,000
-10,000
-18% -$115K 0.01% 207
2025
Q4 		$586K Sell
57,000
-10,334
-15% -$87.1K 0.01% 178
2025
Q3 		$3.91M Buy
+67,334
New +$394K 0.04% 125

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cantor Fitzgerald's TRDA Position: Q1 2026 in Review

Cantor Fitzgerald reduced its Entrada Therapeutics (TRDA) stake by 18% in Q1 2026, selling an estimated $115K and leaving 47,000 shares worth $593K. The position accounts for 0.01% of the portfolio, ranked #207.

Cantor Fitzgerald first reported a position in TRDA in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.91M in Q3 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Cantor Fitzgerald held 47,000 shares of Entrada Therapeutics worth $593K as of Q1 2026.
  • Cantor Fitzgerald sold 10,000 Entrada Therapeutics shares in Q1 2026, an estimated $115K.
  • Entrada Therapeutics made up 0.01% of Cantor Fitzgerald's portfolio in Q1 2026, its #207 holding.
  • Cantor Fitzgerald first reported a position in Entrada Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Cantor Fitzgerald's Entrada Therapeutics position peaked at $3.91M in Q3 2025.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Cantor Fitzgerald's 13F filing for Q1 2026, filed 15 May 2026.